Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

被引：0
|
作者：
Åsa Ericsson
Adam Lundqvist
机构：
[1] Novo Nordisk Scandinavia AB,
[2] IHE,undefined
[3] The Swedish Institute for Health Economics,undefined
来源：
Applied Health Economics and Health Policy | 2017年 / 15卷
关键词：
Liraglutide; Insulin Glargine; Basal Insulin; Insulin Aspart; Insulin Detemir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：237 / 248
页数：11
相关论文
共 50 条
  • [31] IDegLira, a combination of insulin degludec and liraglutide, improves both pre- and postprandial plasma glucose in patients with type 2 diabetes
    King, A.
    Philis-Tsimikas, A.
    Langbakke, I. H.
    Kvist, K.
    Vilsboll, T.
    DIABETOLOGIA, 2014, 57 : S108 - S109
  • [32] Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes
    Junko Oya
    Tomoko Nakagami
    Yukiko Hasegawa
    Yuichiro Kondo
    Aki Katamine
    Mika Shimizu
    Ryo Kubota
    Rika Suda
    Tetsuya Babazono
    Diabetology International, 2024, 15 : 237 - 243
  • [33] Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi
    Pohlmann, Johannes
    Russel-Szymczyk, Monika
    Holik, Pavel
    Rychna, Karel
    Hunt, Barnaby
    DIABETES THERAPY, 2019, 10 (02) : 493 - 508
  • [34] Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes
    Stewart Harris
    Martin J. Abrahamson
    Antonio Ceriello
    Guillaume Charpentier
    Marc Evans
    Roger Lehmann
    Andreas Liebl
    Sultan Linjawi
    Richard I. G. Holt
    Nóra Hosszúfalusi
    Guy Rutten
    Tina Vilsbøll
    Drugs, 2020, 80 : 147 - 165
  • [35] Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi
    Johannes Pöhlmann
    Monika Russel-Szymczyk
    Pavel Holík
    Karel Rychna
    Barnaby Hunt
    Diabetes Therapy, 2019, 10 : 493 - 508
  • [36] The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting
    Drummond, Russell
    Malkin, Samuel
    Du Preez, Michelle
    Lee, Xin Ying
    Hunt, Barnaby
    DIABETES OBESITY & METABOLISM, 2018, 20 (10): : 2371 - 2378
  • [37] Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
    Minze, Molly G.
    Chastain, Lisa M.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 471 - 478
  • [38] A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges
    King, Allen B.
    Philis-Tsimikas, Athena
    Kilpatrick, Eric S.
    Langbakke, Irene H.
    Begtrup, Kamilla
    Vilsboll, Tina
    DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (04) : 255 - 264
  • [39] Triglyceride Reduction and Effect on Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus Receiving Fixed-Dose Combination of Insulin Degludec and Liraglutide
    Pappa, Eleni
    Kostara, Christina
    Dimou, Aikaterini
    Bairaktari, Eleni T.
    Tsimihodimos, Vasilis
    DIABETES, 2021, 70
  • [40] Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes
    Sarah L. Greig
    Lesley J. Scott
    Drugs, 2015, 75 : 1523 - 1534
12345